Mirtazapine for Symptomatic Relief on a Psychiatric Consultation Service: A Case Series

详细信息    查看全文

• 作者：Nicholas D. Allen ; M.D.^a ; ^{allen.nicholas@mayo.edu" class="auth_mail" title="E-mail the corresponding author} ; Jonathan G. Leung ; Pharm.D. ; R.Ph.^b ; Hannah K. Betcher ; M.D.^a ; Kristin L. Borreggine ; D.O.^a ; Daniel K. Hosker ; M.D.^a ; Blaine A. Minton ; D.O.^a ; Eliza M. Sukiennik ; M.D.^a ; Jacob J. Wilson ; M.D.^a ; Kemuel L. Philbrick ; M.D.^a ; Keith G. Rasmussen ; M.D.^a
• 关键词：Consultation Liaison Psychiatry ; antidepressants ; psychopharmacology ; sleep ; nausea ; appetite ; pain
• 刊名：Psychosomatics
• 出版年：2016
• 出版时间：July-August 2016
• 年：2016
• 卷：57
• 期：4
• 页码：409-413
• 全文大小：147 K

文摘

With a complex pharmacologic profile, mirtazapine may promote sleep, stimulate appetite, improve nausea, and reduce pain. Some practitioners working on the Mayo Clinic inpatient psychiatric consultation/liaison service have recommended mirtazapine in medically ill patients with or without formal psychiatric comorbidity to target these symptoms.

Objective

To assess the success of this practice, we conducted a retrospective chart review covering a 4.5-year period.

Methods

For patients recommended to start mirtazapine, global improvement in specific symptoms and suspected side effects were recorded.

Results

During the study period, 528 medically ill patients started mirtazapine following a recommendation from the psychiatric consultation service. In total, 475 patients were provided mirtazapine to specifically target sleep, nausea, pain, or appetite. There was documented improvement in these symptoms for 37.7%, 37.0%, 36.4%, and 23.5% of the patients, respectively. These rates of improvement are conservative for the 229 patients without documented response, i.e., 48% of the patients who were given the medication for a somatic symptom were counted as having no improvement. Commonly documented adverse effects were daytime sedation (5.3%), worsening mental status (2.3%), and nightmares (1%).

Conclusions

Despite the limitations of this retrospective, qualitative study, these data confirm that mirtazapine is generally well tolerated and can provide at least short-term relief of certain symptoms in medically ill patients. Controlled trials are needed to assess these benefits more systematically, and it is not clear how long mirtazapine should be used for these symptoms.